ANTI-LAG-3 MONOCLONAL ANTIBODY, AND ANTIGEN-BINDING FRAGMENT AND APPLICATION THEREOF

WIPO Patent Application WO/2022/121720

A1

The present invention relates to the field of biomedicines, and specifically provides an anti-LAG-3 monoclonal antibody, and an antigen-binding fragment and an application thereof. The anti-LAG-3 monoclonal antibody comprises a heavy chain variable region and a light chain variable region. The monoclonal antibody or the antigen-binding fragment thereof is selected from any one of A-1, A-2, A-3, and A-4. The provided monoclonal antibody can specifically bind to LAG-3, has higher affinity, has good biological activity, and can be used for treating a plurality of cancers or immune diseases. The cancers comprise leukemia, lung cancer, gastric cancer, esophageal cancer, ovarian cancer, head and neck cancer, melanoma, renal cancer, breast cancer, colorectal cancer, liver cancer, pancreatic cancer, and bladder cancer. The immune diseases comprise psoriasis, Crohn's disease, rheumatoid arthritis, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, ulcerative colitis, and autoimmune hepatitis.

WO/1992/000083	PLATELET FIBRINOGEN-SPECIFIC MONOCLONAL ANTIBODY
JP4891769	Treatment methods and bioassays that include macrophage migration inhibitory factor (MIF) as a cardiac-derived myocardial suppressor
WO/1997/010258	ANTIBODIES AGAINST EPITOPES, EXPOSED ON SURFACES OF CANCER CELLS OUTSIDE DESMOSOMES, OF DESMOSOMAL CADHERINES

BAI YI (CN)
ZHOU JUNJIE (CN)
LIU SI (CN)

PCT/CN2021/133941

June 16, 2022

November 29, 2021

Click for automatic bibliography generation  

BEIJING DONGFANG BIOTECH CO LTD (CN)
BEIJING JINGYITAIXIANG TECH DEVELOPMENT CO LTD (CN)

C07K16/28; A61K39/395; A61P35/00; C12N5/10; C12N15/13; C12N15/85

CN110023337A	2019-07-16
CN110305215A	2019-10-08
CN111620949A	2020-09-04
US20180326054A1	2018-11-15
CN105992595A	2016-10-05
CN103525868A	2014-01-22
CN201510312910A	2015-06-09

PEREZ-SANTOS MARTIN, ANAYA-RUIZ MARICRUZ, CEBADA JORGE, BANDALA CINDY, LANDETA GERARDO, MARTÍNEZ-MORALES PATRICIA, VILLA-RUANO NEM: "LAG-3 antagonists by cancer treatment: a patent review", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 29, no. 8, 3 August 2019 (2019-08-03), GB , pages 643 - 651, XP009537414, ISSN: 1354-3776, DOI: 10.1080/13543776.2019.1642873
MATTHEW KRAMAN, MUSTAPHA FAROUDI, NATALIE L. ALLEN, KATARZYNA KMIECIK, DANIEL GLIDDON, CLAIRE SEAL, ALEXANDER KOERS, MATEUSZ M. WY: "FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 26, no. 13, 1 July 2020 (2020-07-01), US, pages 3333 - 3344, XP055722366, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-19-3548
YU XIAOJIE, HUANG XIAO, CHEN XIUXIU, LIU JIANFEI, WU CHENGLIN, PU QIAN, WANG YUXIAO, KANG XIAOQIANG, ZHOU LIJUN: "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy", MABS, LANDES BIOSCIENCE, US, vol. 11, no. 6, 18 August 2019 (2019-08-18), US , pages 1139 - 1148, XP055825981, ISSN: 1942-0862, DOI: 10.1080/19420862.2019.1629239
WORKMAN CJ ET AL., J. IMMUNOL., vol. 174, 2005, pages 688 - 695
JOURNAL OF IMMUNOLOGICAL METHODS, vol. 233, 2000, pages 167 - 177

RUNPING & PARTNERS (CN)

View/Download PDF      PDF Help

Previous Patent: MAGNETIC SUCTION BASE APPLICABLE IN MOBILE PHONE SUPPORT FRAME

Next Patent: LAMP